TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ Ltd announced positive results from in vitro studies of its CAR-NK-exosome therapeutic candidate, which demonstrated potent anti-tumor activity against Triple Negative Breast Cancer (TNBC) cells. The study, conducted at the Peter MacCallum Cancer Centre, showed that over 90% of TNBC cells were killed within 10 hours of treatment, highlighting the potential of CAR-NK-exosomes as a next-generation, cell-free therapy for solid tumors. These findings pave the way for further in vivo studies and clinical development, potentially impacting the company’s operations and positioning in the cancer treatment industry.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology, focusing on advancing next-generation diagnostics and therapeutics to transform cancer care. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancer detection, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 92,058
Technical Sentiment Signal: Sell
Current Market Cap: A$44.65M
See more insights into IIQ stock on TipRanks’ Stock Analysis page.